Literature DB >> 27105548

The use of electrodessication in the treatment of cutaneous neurofibromatosis: A retrospective patient satisfaction outcome assessment.

C G Lutterodt1, A Mohan2, N Kirkpatrick2.   

Abstract

INTRODUCTION: Neurofibromatosis I (NF-1) is an autosomal dominant disease giving rise to hundreds of cutaneous neurofibromas. In addition to localised symptoms such as pain and pruritus, these lesions can have a devastating psychosocial impact. To date, there is no consensus on the optimal management of these lesions. We present the clinical and patient-reported outcomes of a series of NF-1 patients treated with electrodessication by one surgeon.
METHODS: All patients treated by electrodessication for cutaneous neurofibromas between 2012 and 2015 by one clinician were retrospectively reviewed. Clinical and patient-reported outcomes were measured using a patient satisfaction questionnaire and review of the notes.
RESULTS: Six patients were operated on during the study period (five women and one man). Prior to this new technique, patients had on average eight episodes (range 4-20) of excisional procedures under local anaesthesia removing one to five lesions. With electrodessication, patients had on average three (range 1-5) electrodessication episodes under general anaesthesia, treating hundreds of lesions per session. All patients were treated as a day case. One patient experienced a minor wound infection and another minor bleeding. Five of six patients preferred electrodessication to surgical excision.
CONCLUSION: Electrodessication enables the treatment of hundreds of neurofibromas in a single operation. The procedure has low complication rates with high levels of clinical and patient-reported outcomes.
Copyright © 2016 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Benign skin lesion; Cutaneous lesions; Electrodessication; Neurofibroma; Neurofibromatosis; Neurofibromatosis type I

Mesh:

Year:  2016        PMID: 27105548     DOI: 10.1016/j.bjps.2016.03.024

Source DB:  PubMed          Journal:  J Plast Reconstr Aesthet Surg        ISSN: 1748-6815            Impact factor:   2.740


  7 in total

Review 1.  Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment.

Authors:  Shreya S Bellampalli; Rajesh Khanna
Journal:  Pain       Date:  2019-05       Impact factor: 6.961

2.  The recurrent plexiform neurofibroma of the scalp in neurofibromatosis type 1: illustrative case.

Authors:  Galih Indra Permana; M Arifin Parenrengi; Wihasto Suryaningtyas; Dyah Fauziah; Muhammad Azzam
Journal:  J Neurosurg Case Lessons       Date:  2021-01-11

3.  Clinical picture and treatment of cutaneous lesions in patients with neurofibromatosis type 1.

Authors:  Marta Fijałkowska; Bogusław Antoszewski
Journal:  Postepy Dermatol Alergol       Date:  2020-11-07       Impact factor: 1.837

4.  Neurofibromatosis Type 1: Review of Cutaneous and Subcutaneous Tumor Treatment on Quality of Life.

Authors:  Lawrence A Taylor; Victor L Lewis
Journal:  Plast Reconstr Surg Glob Open       Date:  2019-01-18

5.  Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966.

Authors:  Christina Bergqvist; Amandine Servy; Laurence Valeyrie-Allanore; Salah Ferkal; Patrick Combemale; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2020-02-03       Impact factor: 4.123

6.  Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Douglas R Stewart; Bruce R Korf; Katherine L Nathanson; David A Stevenson; Kaleb Yohay
Journal:  Genet Med       Date:  2018-04-26       Impact factor: 8.822

Review 7.  Cutaneous neurofibromas in the genomics era: current understanding and open questions.

Authors:  Robert J Allaway; Sara J C Gosline; Salvatore La Rosa; Pamela Knight; Annette Bakker; Justin Guinney; Lu Q Le
Journal:  Br J Cancer       Date:  2018-04-26       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.